Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03026036 · ClinicalTrials.gov registry record

Neuroimaging Studies of Reward Processing in Depression

A clinical trial, sponsored by Mclean Hospital.

Completed
Registry status
123
Enrollment target

NCT03026036 is a clinical trial that has completed, run by Mclean Hospital. The registered enrollment target is 123 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03026036 has completed, sponsored by Mclean Hospital.

COMPLETED
Registry status
123 participants
Enrollment target

Study Summary

This study investigates stress-related signaling of glutamate and dopamine within the reward-processing circuit in Major Depressive Disorder (MDD), and whether they can be used to predict depressive symptoms in the future. This will be achieved through various neuroimaging tools (MRS, fMRI, PET), behavioral tasks, and a naturalistic follow-up design.

Interventions

  • RADIATION PET Scan with Raclopride

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2016-04
Est. Completion 2021-03

Sponsor

Mclean Hospital

140 total trials

What the Registry Record Tells You About NCT03026036

The ClinicalTrials.gov registry entry for NCT03026036 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which PET Scan with Raclopride is the first listed.

NCT03026036 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03026036 about?

NCT03026036 is a clinical study titled "Neuroimaging Studies of Reward Processing in Depression". This study investigates stress-related signaling of glutamate and dopamine within the reward-processing circuit in Major Depressive Disorder (MDD), and whether they can be used to predict depressive symptoms in the future. This will be achieved through various neuroimaging tools (MRS, fMRI, PET), be...

What is the current status of trial NCT03026036?

This trial is currently completed. The enrollment target is 123 participants. The study started on 2016-04. Estimated completion is 2021-03.

What interventions are being tested in trial NCT03026036?

The interventions under investigation include: PET Scan with Raclopride (RADIATION).

Who is sponsoring clinical trial NCT03026036?

This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.